1. 1. van Solinge TS, Nieland L, Chiocca EA, Broekman MLD (2022) Advances in local therapy for glioblastoma - taking the fight to the tumour. Nat Rev Neurol, 18(4): 221-236. [DOI:10.1038/s41582-022-00621-0]

2. Schaff LR and Mellinghoff IK (2023) Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA, 329 (7): 574-587. [DOI:10.1001/jama.2023.0023]

3. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, et al. (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol, 31(32): 4085-91. [DOI:10.1200/JCO.2013.49.6968]

4. Niyazi M, Brada M, Chalmers AJ, Combs SE, Erridge SC, Fiorentino A, et al. (2016) ESTRO-ACROP guideline "target delineation of glioblastomas". Radiother Oncol, 118(1): 35-42. [DOI:10.1016/j.radonc.2015.12.003]

5. Ermiş E, Jungo A, Poel R, Blatti-Moreno M, Meier R, Knecht U, et al. (2020) Fully automated brain resection cavity delineation for radiation target volume definition in glioblastoma patients using deep learning. Radiat Oncol, 15(1): 100. [DOI:10.1186/s13014-020-01553-z]

6. Zheng L, Zhou ZR, Yu Q, Shi M, Yang Y, Zhou X, et al. (2021) The definition and delineation of the target area of radiotherapy based on the recurrence pattern of glioblastoma after temozolomide chemoradiotherapy. Front Oncol, 10: 615368. [DOI:10.3389/fonc.2020.615368]

7. Minniti G, Tini P, Giraffa M, Capone L, Raza G, Russo I, et al. (2023) Feasibility of clinical target volume reduction for glioblastoma treated with standard chemoradiation based on patterns of failure analysis. Radiother Oncol, 181: 109435. [DOI:10.1016/j.radonc.2022.11.024]

8. Joo L, Park JE, Park SY, Nam SJ, Kim YH, Kim JH, Kim HS (2021) Extensive peritumoral edema and brain-to-tumor interface MRI features enable prediction of brain invasion in meningioma: development and validation. Neuro Oncol, 23(2): 324-333. [DOI:10.1093/neuonc/noaa190]

9. Bijari S, Jahanbakhshi A, Abdolmaleki P (2023) Non-invasive radiomics nomogram model for determining the low and high-grade glioma base on MRI images. Int J Radiat Res; 21 (2): 275-280.

10. Capobianco E and Dominietto M (2023) Assessment of brain cancer atlas maps with multimodal imaging features. J Transl Med 21 (1): 385. [DOI:10.1186/s12967-023-04222-3]

11. Kruser TJ, Bosch WR, Badiyan SN, Bovi JA, Ghia AJ, Kim MM, et al. (2019) NRG brain tumor specialists consensus guidelines for glioblastoma contouring. J Neurooncol, 143(1):157-166. [DOI:10.1007/s11060-019-03152-9]

12. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352(10): 987-96. [DOI:10.1056/NEJMoa043330]

13. Fleischmann DF, Schön R, Corradini S, Bodensohn R, Hadi I, Hofmaier J, et al. (2021) Multifocal high-grade glioma radiotherapy safety and efficacy. Radiat Oncol, 16(1): 165. [DOI:10.1186/s13014-021-01886-3]

14. Niyazi M, Andratschke N, Bendszus M, Chalmers AJ, Erridge SC, Galldiks N, et al. (2023) ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma. Radiother Oncol, 184: 109663. [DOI:10.1016/j.radonc.2023.109663]

15. Seaberg MH, Kazda T, Youland RS, Laack NN, Pafundi DH, Anderson SK, et al. (2023) Dosimetric patterns of failure in the era of novel chemoradiotherapy in newly-diagnosed glioblastoma patients. Radiother Oncol, 188: 109768. [DOI:10.1016/j.radonc.2023.109768]

16. Bernchou U, Arnold TST, Axelsen B, Klüver-Kristensen M, Mahmood F, Harbo FSG,et al.(2021) Evolution of the gross tumour volume extent during radiotherapy for glioblastomas. Radiother Oncol, 160: 40-46. [DOI:10.1016/j.radonc.2021.04.001]

17. Tu Z, Xiong H, Qiu Y, Li G, Wang L, Peng S (2021) Limited recurrence distance of glioblastoma under modern radiotherapy era. BMC Cancer, 21(1): 720. [DOI:10.1186/s12885-021-08467-3]

18. Elmtalab S and Abedi I (2021) Investigating the out-of-field doses and estimating the risk of secondary thyroid cancer in high-grade gliomas radiation therapy with modulated intensity and 3D-conformal: a phantom study. International Journal of Radiation Research 19 (3):569-574. [DOI:10.52547/ijrr.19.3.569]

19. Huang J, DeWees TA, Badiyan SN, Speirs CK, Mullen DF, Fergus S, et al. (2015) Clinical and Dosimetric predictors of acute severe lymphopenia during radiation therapy and concurrent temozolomide for high-grade glioma. Int J Radiat Oncol Biol Phys, 92(5): 1000-1007. [DOI:10.1016/j.ijrobp.2015.04.005]

20. Ogura K, Mizowaki T, Arakawa Y, Ogura M, Sakanaka K, Miyamoto S, Hiraoka M. (2013) Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution. Radiat Oncol, 8: 97. [DOI:10.1186/1748-717X-8-97]

21. Guberina N, Padeberg F, Pöttgen C, Guberina M, Lazaridis L, Jabbarli R, et al. (2023) Location of Recurrences after Trimodality Treatment for Glioblastoma with Respect to the Delivered Radiation Dose Distribution and Its Influence on Prognosis. Cancers (Basel), 15(11): 2982. [DOI:10.3390/cancers15112982]

22. Zhu H and Luo J (2023) Postoperative intensity-modulated radiotherapy and chemotherapy in patients with high-grade glioma: analysis of efficacy and prognostic factors. International Journal of Radiation Research 21 (1): 139-145.

23. Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, et al. (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomized, open-label, phase 3 trial. Lancet (London, England) 393 (10172): 678-688. [DOI:10.1016/S0140-6736(18)31791-4]

24. Fisher JP and Adamson DC (2021) Current FDA-Approved Therapies for High-Grade Malignant Gliomas. Biomedicines 9 (3): 324. [DOI:10.3390/biomedicines9030324]

25. Nozhat Z, Heydarzadeh S, Shahriari-Khalaji M, Wang S, Iqbal MZ, Kong X (2023) Advanced biomaterials for human glioblastoma multiforme (GBM) drug delivery. Biomater Sci 11 (12): 4094-4131. [DOI:10.1039/D2BM01996E]

26. Schreck KC, Strowd RE, Nabors LB, Ellingson BM, Chang M, Tan SK, et al. (2024) Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma. Clin Cancer Res, 30(10): 2048-2056. [DOI:10.1158/1078-0432.CCR-23-3241]

27. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 131 (6): 803-820. [DOI:10.1007/s00401-016-1545-1]